No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

Remdesivir (RDV) is a broad-spectrum nucleotide analog prodrug approved for the treatment of COVID-19 in hospitalized and non-hospitalized patients with clinical benefit demonstrated in multiple Phase 3 trials. Here we present SARS-CoV-2 resistance analyses from the Phase 3 SIMPLE clinical studies e...

詳細記述

書誌詳細

主要な著者:	Charlotte Hedskog, Christoph D. Spinner, Ulrike Protzer, Dieter Hoffmann, Chunkyu Ko, Robert L. Gottlieb, Medhat Askar, Meta Roestenberg, Jutte J. C. de Vries, Ellen C. Carbo, Ross Martin, Jiani Li, Dong Han, Lauren Rodriguez, Aiyappa Parvangada, Jason K. Perry, Ricard Ferrer, Andrés Antón, Cristina Andrés, Vanessa Casares, Huldrych F. Günthard, Michael Huber, Grace A. McComsey, Navid Sadri, Judith A. Aberg, Harm van Bakel, Danielle P. Porter
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-03-01
シリーズ:	Viruses
主題:	remdesivir SARS-CoV-2 resistance genotyping phenotyping Nsp12
オンライン･アクセス:	https://www.mdpi.com/1999-4915/16/4/546
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!